<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>Aeviant Biosciences Writing</title>
    <link>https://www.aeviant.com/writing/</link>
    <description>Articles and research notes from Aeviant Biosciences.</description>
    <language>en-CA</language>
    <lastBuildDate>Mon, 20 Jul 2026 00:00:00 GMT</lastBuildDate>
    <atom:link href="https://www.aeviant.com/feed.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>When Disease Becomes Part of the Design</title>
      <link>https://www.aeviant.com/writing/biological-state-in-drug-design/</link>
      <guid isPermaLink="true">https://www.aeviant.com/writing/biological-state-in-drug-design/</guid>
      <description>How biological state could become a variable in therapeutic control.</description>
      <pubDate>Mon, 13 Jul 2026 00:00:00 GMT</pubDate>
      <dc:creator>Immanuel Martins</dc:creator>
      <category>biological state</category>
      <category>drug design</category>
      <category>state-dependent pharmacology</category>
      <category>biological feedback</category>
      <category>physiological regulation</category>
    </item>
  </channel>
</rss>
